The Capital Markets Recovery

The biotechnology sector is emerging from a protracted "capital winter." After the cyclical nadir of 2025—characterised by depressed valuations, stagnant IPO volume, and a flight of generalist capital—public markets are experiencing a structured resurgence. As macroeconomic headwinds ease and large-cap pharmaceutical companies seek to backfill their pipelines ahead of looming patent cliffs, institutional and generalist investors are returning to life sciences.

However, the terms of engagement have fundamentally changed. The speculative, platform-narrative valuations of the pandemic era have been replaced by a strict "quality over quantity" mandate. Today's public markets demand clinical validation, operational maturity, and institutional-grade governance. For private, venture-backed biotechs preparing for public listings, de-risking their valuation is no longer just a scientific challenge—it is a governance imperative.

The Governance Discount

In a highly selective market, investors heavily discount public listings perceived as having weak corporate controls or legacy founder-dominated boards. A private biotech can operate with an insider-dominated, venture-aligned board; a public biotech cannot.

The return of generalist investors has brought heightened scrutiny to two key areas of corporate governance:

• Internal Controls and Reporting: Boards must demonstrate that their financial reporting, audit frameworks, and data integrity systems meet the compliance standards required by public markets (such as SEC and FCA rules). Weakness in these internal controls leads directly to valuation discounts during the IPO pricing phase.

• Shareholder Activism and Engagement: Public listings expose biotechs to public market volatility and the risk of activist investor campaigns. Boards must proactively manage shareholder relations, establish transparent communication protocols, and implement defensive structures that protect the company’s clinical timeline from short-term market pressures.

Strategic Board Refreshment: From Science to Commercialisation

To meet these heightened expectations, biotech boards must undergo a structured professionalisation process. The board composition that successfully guided a company through preclinical discovery and Series A/B rounds is rarely the optimal team to govern a public company entering Phase II/III trials or preparing for commercial launch.

IPOs are increasingly dependent on refreshing the board with independent directors who possess specific public market expertise:

• Capital Markets and M&A Fluency: Directors who have steered public offerings, managed institutional investor relations through clinical trial readouts, and structured licensing or M&A transactions.

• Commercialisation and Launch Oversight: Board members who have taken drugs from Phase III validation through global launch, providing oversight on pricing, reimbursement, and market access strategies.

• Audit and Compliance Leadership: Independent audit committee chairs capable of establishing public-grade financial controls and ensuring compliance with evolving ESG and transparency regulations.

The Talent Mandate: Sourcing Public-Ready Directors

As private biotechs prepare for public market entry, the competition for experienced, independent board directors has intensified. Recruiting a board of scientific founders and venture partners is no longer sufficient to secure institutional investor support.

RSA’s board advisory practice prioritises several criteria when placing independent directors in pre-IPO and public biotech portfolios:

• Public-Board Experience: A proven track record of serving on public boards within the life sciences sector, demonstrating familiarity with regulatory compliance, disclosure rules, and proxy season governance.

• Cognitive Diversity and Therapeutic Alignment: Balancing the board’s scientific expertise with commercial, financial, and operational perspectives aligned with the company’s target therapeutic pipeline.

• Independence and Objectivity: Candidates who can provide objective oversight, representing the interests of all public shareholders and satisfying regulatory independence criteria.

Professionalising the board is the single most effective way to de-risk a biotech’s valuation as it enters the public market. By transitioning from a science-first private board to a commercial-ready public board, biotechs establish the credibility required to capture institutional capital and sustain long-term growth.